Cited by 124Protein Degradation and InhibitorsAutophagy in Disease and TherapyUbiquitin and proteasome pathways

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery

Pei, Junping, Wang, Guan, Feng, Lu, Zhang, Jifa, Jiang, Tingting, Sun, Qiu, Ouyang, Liang·2021·Journal of Medicinal Chemistry

Abstract

A series of tools for targeted protein degradation are inspiring scientists to develop new drugs with advantages over traditional small-molecule drugs. Among these tools, proteolysis-targeting chimeras (PROTACs) are most representative of the technology based on proteasomes. However, the proteasome has little degradation effect on certain macromolecular proteins or aggregates, extracellular proteins, and organelles, which limits the application of PROTACs. Additionally, lysosomes play an important role in protein degradation. Therefore, lysosome-induced protein degradation drugs can directly regulate protein levels in vivo, achieve the goal of treating diseases, and provide new strategies for drug discovery. Lysosome-based degradation technology has the potential for clinical translation. In this review, strategies targeting lysosomal pathways and lysosome-based degradation techniques are summarized. In addition, lysosome-based degrading drugs are described, and the advantages and challenges are listed. Our efforts will certainly promote the design, discovery, and clinical application of drugs associated with this technology.

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.0c01689

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LYTACs are chimeric molecules that combine cell surface lysosomal targeting receptors and extracellular or membrane proteins to expand TPD to extracellular targets; Bertozzi's group developed the first LYTAC molecule, Ab-2, by fusing cetuximab with an M6P-modified peptide, and Ab-2 significantly reduced EGFR levels in HeLa cells.

    “Consequently, researchers have proposed lysosomal targeting chimera technologies (LYTACs), chimeric molecules that combine cell surface lysosomal targeting receptors and extracellular or membrane proteins, to expand TPD technologies to extracellular targets. Bertozzi’s group at Stanford University developed the first LYTAC molecule, Ab-2, by fusing cetuximab (ctx), a monoclonal antibody targeting”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pei, J., Wang, G., Feng, L., Zhang, J., Jiang, T., Sun, Q., & Ouyang, L.
Affiliations
Sichuan University (CN)
Corresponding author
  • Sun, Qiu
  • Ouyang, Liang
Venue
Journal of Medicinal Chemistry
Published
2021-03-25
Volume
64
Issue
7
Pages
3493-3507
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W3139366518
Cited by
124
References
117
Citations by year
2026: 20 · 2025: 23 · 2024: 29 · 2023: 28 · 2022: 13 · 2021: 9 · 2014: 1
FWCI
2.15
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Department of Science and Technology of Sichuan Province (2019JDRC0091)
  • National Natural Science Foundation of China (81803755, 81874290, 81903502, 81922064)
  • National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Z20201004)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
lysosomal degradation, PROTACs, proteasome, protein degradation, drug design
MeSH terms
Autophagosomes, Amino Acid Sequence, Animals, Autophagy, Endocytosis, Humans, Lysosomes, Peptides, Protein Binding, Receptor, IGF Type 2, Drug Discovery, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review